+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hip Osteoarthritis Pain Drug Market by Mechanism Of Action (Corticosteroids, Hyaluronic Acid, Nonsteroidal Anti-Inflammatory Drugs), Route Of Administration (Injectable, Oral, Topical), End User, Patient Age Group - Global Forecast 2025-2030- Product Image
Hip Osteoarthritis Pain Drug Market by Mechanism Of Action (Corticosteroids, Hyaluronic Acid, Nonsteroidal Anti-Inflammatory Drugs), Route Of Administration (Injectable, Oral, Topical), End User, Patient Age Group - Global Forecast 2025-2030- Product Image
New

Hip Osteoarthritis Pain Drug Market by Mechanism Of Action (Corticosteroids, Hyaluronic Acid, Nonsteroidal Anti-Inflammatory Drugs), Route Of Administration (Injectable, Oral, Topical), End User, Patient Age Group - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 180 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6139349
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Setting the Context for Hip Osteoarthritis Pain Treatment Dynamics to Illuminate Emerging Therapeutic and Market Drivers Shaping Industry Evolution

The realm of hip osteoarthritis pain management has entered a pivotal phase marked by evolving therapeutic approaches and shifting stakeholder expectations. Clinicians and patients alike are navigating a spectrum of treatment modalities, each driven by distinct mechanisms of action and varied routes of administration. Initially, traditional anti-inflammatory agents offered symptomatic relief but revealed limitations in durability and safety profiles. As a result, innovative interventions have emerged, leveraging biologic agents and advanced delivery systems to address underlying joint degeneration and improve patient quality of life.

Furthermore, cost pressures across healthcare systems underscore the need for treatments that balance efficacy with economic sustainability. Payers are scrutinizing value propositions more closely, prompting manufacturers to demonstrate real-world outcomes and long-term benefits. Concurrently, patient advocacy has intensified, with individuals demanding personalized care pathways that integrate non-pharmacologic modalities alongside drug therapies. Consequently, collaboration between clinical researchers, technology developers, and regulatory bodies has gained momentum, setting the stage for accelerated product development and streamlined market entry. Moving forward, this landscape demands a holistic understanding of therapeutic innovations, regulatory dynamics, and patient-centric care models that collectively shape the future of hip osteoarthritis pain management.

Charting the Radical Transformation of Hip Osteoarthritis Pain Management Fueled by Technological Breakthroughs and Strategic Industry Realignment

Breakthrough developments in biologics, small molecules, and delivery technologies are transforming the therapeutic landscape for hip osteoarthritis pain. Advancements such as sustained-release injectable formulations and bioengineered hydrogel scaffolds have elevated expectations for both clinicians and patients seeking prolonged relief with reduced adverse effects. At the same time, digital health platforms are enabling remote monitoring of symptom progression and treatment adherence, fostering a connected care model that extends beyond the clinic.

Moreover, regulatory frameworks are adapting to encourage expedited review pathways for therapies that address significant unmet needs. This regulatory agility is complemented by strategic alliances among pharmaceutical companies, academic institutions, and technology startups, coalescing around shared goals of accelerated innovation. Consequently, the traditional boundaries between drug developers and device manufacturers are dissolving, yielding hybrid solutions that combine pharmacologic and mechanical interventions. Looking ahead, the fusion of artificial intelligence-driven insights with real-world evidence is poised to guide precision medicine strategies, ensuring patients receive treatments tailored to their unique clinical profiles.

Evaluating the Cumulative Impact of Imposed US Tariffs on Hip Osteoarthritis Pain Therapeutics in 2025 and Their Ripple Effects Across Supply Chains

In 2025, newly imposed tariffs on imported active pharmaceutical ingredients and excipients have introduced an additional layer of complexity for manufacturers of hip osteoarthritis pain therapeutics. Suppliers are reevaluating sourcing strategies, with many seeking to diversify procurement channels or establish localized production to mitigate cost fluctuations. As a result, upstream players have intensified partnerships with domestic chemical manufacturers, aiming to secure supply chain resilience and maintain consistent product availability.

Simultaneously, formulators are reassessing formulation processes, exploring alternative excipient grades and novel manufacturing techniques to offset the impact of elevated input costs. This drive for optimization is fostering cross-functional collaboration among research and operations teams, accelerating efforts to reformulate existing compounds without compromising safety or efficacy. Consequently, logistical networks are being reconfigured to streamline distribution, reduce lead times, and adhere to revised customs protocols. Ultimately, the tariff landscape of 2025 is catalyzing a strategic shift toward vertical integration and agile supply chain management, ensuring that patient access to critical pain therapies remains uninterrupted.

Unpacking Critical Segmentation Insights to Reveal Mechanism, Delivery Methods, End User Roles, and Patient Age Dynamics in Treatment Markets

Insight into the mechanism of action segmentation reveals that corticosteroids continue to be a mainstay for rapid symptomatic relief, whereas hyaluronic acid injections are gaining traction for their viscoelastic cushioning properties. Nonsteroidal anti-inflammatory drugs hold a well-established position in oral regimens, yet concerns over gastrointestinal safety are prompting a reevaluation of long-term use. Opioids remain reserved for refractory cases, reflecting heightened scrutiny over dependency risks, while serotonin norepinephrine reuptake inhibitors are emerging as an adjunctive option to address chronic pain pathways.

Examining route of administration dynamics illustrates that injectable therapies are benefiting from advancements in delivery systems that prolong therapeutic effects, even as oral formulations offer convenience and patient preference. Topical solutions are carving out a niche for localized symptom control, and transdermal approaches provide a noninvasive alternative with consistent systemic exposure. Transitioning to end user segmentation, ambulatory care centers are capitalizing on outpatient procedures and injection suites to deliver therapies efficiently, while home care settings are expanding offerings to support self-administered regimens. Hospital pharmacies manage complex infusion protocols, and specialty clinics integrate multidisciplinary care models that emphasize personalized treatment plans.

Finally, patient age group segmentation underscores that individuals aged 18 to 45 are driving interest in early intervention strategies that preserve joint integrity. The 46 to 60 cohort is balancing lifestyle demands with long-term management goals, and patients over 60 prioritize treatments that minimize hospital visits and optimize functional independence.

Highlighting Regional Nuances in Hip Osteoarthritis Pain Therapy Across the Americas, EMEA and Asia Pacific Landscapes

Regional analysis of the Americas highlights a mature therapeutic ecosystem driven by strong reimbursement frameworks and well-established distribution channels. This region continues to attract investment in novel biologics and extended-release formulations, supported by a patient population that demands high-touch care models. In Europe, Middle East & Africa, diverse regulatory landscapes and variable healthcare infrastructures are fostering localized innovation hubs, where adaptations of global therapies are tailored to distinct reimbursement environments and clinical guidelines.

Meanwhile, the Asia-Pacific region is experiencing rapid growth in clinical trial activity, with emerging markets demonstrating heightened interest in cost-effective generics and biosimilar alternatives. Governments in key Asia-Pacific economies are incentivizing domestic manufacturing capabilities, thereby reducing reliance on imported ingredients and accelerating regional supply chain development. Simultaneously, the convergence of telemedicine platforms and mobile health applications is enhancing patient engagement across all regions, enabling real-time monitoring and personalized support. Collectively, these regional nuances underscore the importance of tailoring market strategies to address varied regulatory, economic, and patient-centric considerations.

Delving into Competitive Strategies and Innovations of Leading Pharmaceutical Players Driving Progress in Hip Osteoarthritis Pain Drug Development

Leading pharmaceutical and biotechnology companies are leveraging differentiated pipelines and strategic partnerships to maintain competitive advantage in hip osteoarthritis pain management. Major innovators are focusing on next-generation formulations that combine anti-inflammatory molecules with biomodulatory agents, aiming to deliver both symptomatic relief and structural joint support. Concurrently, some firms have pursued licensing agreements with specialized biotech startups to access novel delivery technologies and proprietary biopolymers.

Collaboration between established drug developers and digital health vendors is producing integrated care platforms that pair pharmacologic interventions with remote patient monitoring tools. This convergence is enabling real-time adherence tracking and outcome measurement, providing robust evidence for value-based pricing models. In parallel, select companies are investing in advanced analytics capabilities, applying machine learning algorithms to identify responders and optimize dosing regimens. By aligning R&D investments with evolving payer demands, these organizations are positioning themselves to lead the market in both innovation and sustainable access.

Delivering Targeted Actionable Recommendations to Empower Industry Leaders in Enhancing Therapeutic Access and Competitive Positioning

Industry leaders should prioritize the establishment of integrated supply chain infrastructures that mitigate exposure to tariff volatility by fostering local manufacturing partnerships and securing multiple sourcing agreements. Additionally, investment in real-world evidence generation will reinforce clinical and economic value propositions, facilitating favorable reimbursement outcomes across diverse healthcare systems.

To advance patient engagement, companies are advised to deploy digital support tools that complement core therapies, enabling personalized adherence programs and remote symptom tracking. Developers should also explore collaborations with device manufacturers to co-create combination products that enhance treatment durability and convenience. From a portfolio perspective, diversifying across mechanism of action categories can shift risk exposure and capitalize on emerging therapeutic modalities. Finally, forging alliances with regional stakeholders and tailoring market access strategies to local regulatory frameworks will unlock new growth avenues while reinforcing competitive positioning.

Outlining Rigorous Research Methodology and Multidimensional Analytical Approaches That Underpin the Validity of Market Insights

The analysis underpinning these insights is grounded in a mixed-methods research framework that integrates primary and secondary data collection. Primary inputs include in-depth interviews with key opinion leaders, formulary committee members, clinical trial investigators, and payers across major markets. Secondary research draws on peer-reviewed publications, regulatory documents, company filings, and industry journals to validate findings.

Quantitative analyses employ rigorous data triangulation techniques to ensure reliability, while qualitative thematic analysis provides contextual depth. A structured segmentation approach guides investigation across mechanism of action, route of administration, end-user environment, and patient age group. Regional variations are examined through comparative regulatory and reimbursement assessments, and competitive dynamics are mapped via strategic benchmarking of leading companies. All data undergoes multi-layer validation, ensuring that conclusions rest on a robust evidence base and reflect real-world market dynamics.

Summarizing Strategic Conclusions on the Future Direction of Hip Osteoarthritis Pain Treatment and Implications for Stakeholder Decision Making

In conclusion, the hip osteoarthritis pain management landscape is evolving toward personalized, integrated care models supported by innovative therapies and digital solutions. Stakeholders must navigate shifting regulatory frameworks, rising tariff pressures, and regional nuances to sustain competitive advantage. Strategic diversification across mechanisms of action and routes of administration will mitigate risk and address heterogeneous patient needs.

Moreover, investment in real-world evidence and technology-enabled engagement is critical to securing payer acceptance and enhancing patient outcomes. As the industry moves forward, cross-sector collaboration and agile supply chain strategies will define market leadership. Embracing these imperatives will position organizations to capitalize on emerging opportunities and deliver meaningful advances in patient care.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Mechanism Of Action
    • Corticosteroids
    • Hyaluronic Acid
    • Nonsteroidal Anti-Inflammatory Drugs
    • Opioids
    • Serotonin Norepinephrine Reuptake Inhibitors
  • Route Of Administration
    • Injectable
    • Oral
    • Topical
    • Transdermal
  • End User
    • Ambulatory Care Centers
    • Home Care Settings
    • Hospital Pharmacies
    • Specialty Clinics
  • Patient Age Group
    • 18 To 45 Years
    • 46 To 60 Years
    • Over 60 Years
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Pfizer Inc.
  • Novartis AG
  • Bayer AG
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Sanofi S.A.
  • AstraZeneca PLC
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of personalized hip osteoarthritis pain management through biomarker-driven therapies
5.2. Integration of wearable sensor technology for real-time monitoring of hip osteoarthritis pain and mobility
5.3. Emergence of targeted gene therapies aiming to regenerate hip cartilage in osteoarthritis patients
5.4. Advancements in minimally invasive injection techniques delivering sustained-release analgesics to the hip joint
5.5. Growing adoption of digital health platforms for remote management and patient engagement in hip osteoarthritis treatment
5.6. Development of novel dual-action small molecules addressing both pain and cartilage degradation in hip osteoarthritis
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Hip Osteoarthritis Pain Drug Market, by Mechanism Of Action
8.1. Introduction
8.2. Corticosteroids
8.3. Hyaluronic Acid
8.4. Nonsteroidal Anti-Inflammatory Drugs
8.5. Opioids
8.6. Serotonin Norepinephrine Reuptake Inhibitors
9. Hip Osteoarthritis Pain Drug Market, by Route Of Administration
9.1. Introduction
9.2. Injectable
9.3. Oral
9.4. Topical
9.5. Transdermal
10. Hip Osteoarthritis Pain Drug Market, by End User
10.1. Introduction
10.2. Ambulatory Care Centers
10.3. Home Care Settings
10.4. Hospital Pharmacies
10.5. Specialty Clinics
11. Hip Osteoarthritis Pain Drug Market, by Patient Age Group
11.1. Introduction
11.2. 18 To 45 Years
11.3. 46 To 60 Years
11.4. Over 60 Years
12. Americas Hip Osteoarthritis Pain Drug Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Hip Osteoarthritis Pain Drug Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Hip Osteoarthritis Pain Drug Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Pfizer Inc.
15.3.2. Novartis AG
15.3.3. Bayer AG
15.3.4. GlaxoSmithKline plc
15.3.5. Johnson & Johnson
15.3.6. Merck & Co., Inc.
15.3.7. Sanofi S.A.
15.3.8. AstraZeneca PLC
15.3.9. Teva Pharmaceutical Industries Ltd
15.3.10. Viatris Inc.
16. Research AI17. Research Statistics18. Research Contacts19. Research Articles20. Appendix
List of Figures
FIGURE 1. HIP OSTEOARTHRITIS PAIN DRUG MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. HIP OSTEOARTHRITIS PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. HIP OSTEOARTHRITIS PAIN DRUG MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. HIP OSTEOARTHRITIS PAIN DRUG MARKET: RESEARCHAI
FIGURE 24. HIP OSTEOARTHRITIS PAIN DRUG MARKET: RESEARCHSTATISTICS
FIGURE 25. HIP OSTEOARTHRITIS PAIN DRUG MARKET: RESEARCHCONTACTS
FIGURE 26. HIP OSTEOARTHRITIS PAIN DRUG MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. HIP OSTEOARTHRITIS PAIN DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HYALURONIC ACID, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HYALURONIC ACID, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY OPIOIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY 18 TO 45 YEARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY 18 TO 45 YEARS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY 46 TO 60 YEARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY 46 TO 60 YEARS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY OVER 60 YEARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY OVER 60 YEARS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 61. UNITED STATES HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 62. UNITED STATES HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 63. UNITED STATES HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 64. UNITED STATES HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 69. CANADA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 70. CANADA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 71. CANADA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 72. CANADA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 73. CANADA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 74. CANADA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 75. CANADA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 76. CANADA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 77. MEXICO HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 78. MEXICO HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 79. MEXICO HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 80. MEXICO HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 81. MEXICO HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. MEXICO HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. MEXICO HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 84. MEXICO HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 85. BRAZIL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 86. BRAZIL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 87. BRAZIL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 88. BRAZIL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 89. BRAZIL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 90. BRAZIL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 91. BRAZIL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 92. BRAZIL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 93. ARGENTINA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 94. ARGENTINA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 95. ARGENTINA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 96. ARGENTINA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 97. ARGENTINA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 98. ARGENTINA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 99. ARGENTINA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 100. ARGENTINA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 112. UNITED KINGDOM HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 114. UNITED KINGDOM HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 116. UNITED KINGDOM HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 118. UNITED KINGDOM HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 119. GERMANY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 120. GERMANY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 121. GERMANY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 122. GERMANY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 123. GERMANY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. GERMANY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. GERMANY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 126. GERMANY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 127. FRANCE HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 128. FRANCE HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 129. FRANCE HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 130. FRANCE HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 131. FRANCE HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. FRANCE HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. FRANCE HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 134. FRANCE HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 135. RUSSIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 136. RUSSIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 137. RUSSIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 138. RUSSIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 139. RUSSIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 140. RUSSIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 141. RUSSIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 142. RUSSIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 143. ITALY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 144. ITALY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 145. ITALY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. ITALY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. ITALY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 148. ITALY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 149. ITALY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 150. ITALY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 151. SPAIN HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 152. SPAIN HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 153. SPAIN HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 154. SPAIN HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 155. SPAIN HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. SPAIN HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. SPAIN HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 158. SPAIN HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 159. UNITED ARAB EMIRATES HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 160. UNITED ARAB EMIRATES HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 161. UNITED ARAB EMIRATES HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 167. SAUDI ARABIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 168. SAUDI ARABIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 169. SAUDI ARABIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 170. SAUDI ARABIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. SAUDI ARABIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 174. SAUDI ARABIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 175. SOUTH AFRICA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 176. SOUTH AFRICA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 177. SOUTH AFRICA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 178. SOUTH AFRICA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 179. SOUTH AFRICA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. SOUTH AFRICA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 182. SOUTH AFRICA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 183. DENMARK HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 184. DENMARK HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 185. DENMARK HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 186. DENMARK HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 187. DENMARK HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 188. DENMARK HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 189. DENMARK HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 190. DENMARK HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 191. NETHERLANDS HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 192. NETHERLANDS HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 193. NETHERLANDS HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 194. NETHERLANDS HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 195. NETHERLANDS HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. NETHERLANDS HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. NETHERLANDS HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 198. NETHERLANDS HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 199. QATAR HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 200. QATAR HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 201. QATAR HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 202. QATAR HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 203. QATAR HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. QATAR HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. QATAR HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 206. QATAR HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 207. FINLAND HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 208. FINLAND HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 209. FINLAND HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 210. FINLAND HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 211. FINLAND HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. FINLAND HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. FINLAND HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 214. FINLAND HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 215. SWEDEN HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 216. SWEDEN HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 217. SWEDEN HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 218. SWEDEN HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 219. SWEDEN HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. SWEDEN HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. SWEDEN HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 222. SWEDEN HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 223. NIGERIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 224. NIGERIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 225. NIGERIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 226. NIGERIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 227. NIGERIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. NIGERIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. NIGERIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 230. NIGERIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 231. EGYPT HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 232. EGYPT HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 233. EGYPT HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 234. EGYPT HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 235. EGYPT HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. EGYPT HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. EGYPT HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 238. EGYPT HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 239. TURKEY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 240. TURKEY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 241. TURKEY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 242. TURKEY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 243. TURKEY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 244. TURKEY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 245. TURKEY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 246. TURKEY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 247. ISRAEL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 248. ISRAEL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 249. ISRAEL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 250. ISRAEL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 251. ISRAEL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. ISRAEL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. ISRAEL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 254. ISRAEL HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 255. NORWAY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 256. NORWAY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 257. NORWAY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 258. NORWAY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 259. NORWAY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. NORWAY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. NORWAY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 262. NORWAY HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 263. POLAND HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 264. POLAND HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 265. POLAND HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 266. POLAND HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 267. POLAND HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. POLAND HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. POLAND HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 270. POLAND HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 271. SWITZERLAND HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 272. SWITZERLAND HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 273. SWITZERLAND HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 274. SWITZERLAND HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 275. SWITZERLAND HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. SWITZERLAND HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. SWITZERLAND HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 278. SWITZERLAND HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 279. ASIA-PACIFIC HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 280. ASIA-PACIFIC HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 281. ASIA-PACIFIC HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 282. ASIA-PACIFIC HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 283. ASIA-PACIFIC HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 284. ASIA-PACIFIC HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 285. ASIA-PACIFIC HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 286. ASIA-PACIFIC HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 287. ASIA-PACIFIC HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 288. ASIA-PACIFIC HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 289. CHINA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 290. CHINA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 291. CHINA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 292. CHINA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 293. CHINA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 294. CHINA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 295. CHINA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 296. CHINA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 297. INDIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 298. INDIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 299. INDIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 300. INDIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 301. INDIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 302. INDIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 303. INDIA HIP OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Hip Osteoarthritis Pain Drug Market report include:
  • Pfizer Inc.
  • Novartis AG
  • Bayer AG
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Sanofi S.A.
  • AstraZeneca PLC
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc.

Related Topics

Related Reports

Japan Osteoarthritis Therapeutics Market Report and Forecast 2025-2034 - Product Image

Japan Osteoarthritis Therapeutics Market Report and Forecast 2025-2034

  • Report
  • 250 Pages
  • Japan
From
Brazil Osteoarthritis Therapeutics Market Report and Forecast 2025-2034 - Product Image

Brazil Osteoarthritis Therapeutics Market Report and Forecast 2025-2034

  • Report
  • 250 Pages
  • Brazil
From
Osteoarthritis Therapeutics Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034) - Product Image

Osteoarthritis Therapeutics Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)

  • Report
  • 400 Pages
  • Global
From
Osteoarthritis Therapeutics - Global Strategic Business Report - Product Image

Osteoarthritis Therapeutics - Global Strategic Business Report

  • Report
  • 266 Pages
  • Global
From
Osteoarthritis Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021 - 2031 - Product Image

Osteoarthritis Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021 - 2031

  • Drug Pipelines
  • 131 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.